Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: Will Roche be the last to know?

This article was originally published in Scrip

Executive Summary

In late 2000 when I was a fresh-faced investor just out of the anti-infectives group at SmithKline Beecham (SB), a colleague took me up to Manchester to see one of 3i's then private investments called NeuTec Pharma. During the meeting I had to point out that NeuTec's estimates for its lead product were 95% too high because they were mistakenly based on the largest instead of the smallest variant of the product that I had been managing at SB until a few months earlier. Imagine my surprise a few years later – after NeuTec's IPO and after 3i had divested its holding because NeuTec's products were all still un-partnered – when Novartis (which our fund owns) acquired NeuTec for $305m (scripintelligence.com, 09 June 2006).

You may also be interested in...



Stockwatch: Repeating Past Mistakes At AbbVie

AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.

Stockwatch: Coronavirus And Commercialization

The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.

Stockwatch: Coronavirus And The Pharmaceutical Value Chain

Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026216

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel